Cantor Fitzgerald Reiterates a Buy Rating on Bruker Corp.

By Jason Carr

In a report released today, Bryan Brokmeier from Cantor Fitzgerald reiterated a Buy rating on Bruker Corp. (NASDAQ: BRKR), with a price target of $28. The company’s shares opened today at $22.65.

Brokmeier observed:

“3Q16 Results Summary. 3Q16 total revenues of $393.9M (down 0.6% y/y, and down 2.4% organically), was $1.0M below our estimate of $394.9M, and $1.4M below FactSet consensus of $395.3M. Adjusted cash EPS of $0.32 was $0.13 above our estimate of $0.19 and $0.12 above consensus of $0.20. More within. Slightly reduced 2016 revenue guidance, but raised EPS guidance. Management reduced 2016 revenue growth guidance to a decline of 1% y/y, which implies revenue of $1.61B, compared to our prior estimate and consensus of $1.62B. Despite the lower revenue guidance, the company raised adjusted EPS guidance to $1.07-$1.11, from prior $0.97-$1.02.”

According to TipRanks.com, Brokmeier is ranked 0 out of 5 stars with an average return of -6.4% and a 34.4% success rate. Brokmeier covers the Healthcare sector, focusing on stocks such as Rosetta Genomics Ltd, Pacific Biosciences, and Laboratory Corp.

Bruker Corp. has an analyst consensus of Moderate Buy.

Based on Bruker Corp.’s latest earnings report from June 30, the company posted quarterly revenue of $371.7M and quarterly net profit of $14.5M. In comparison, last year the company earned revenue of $396.1M and had a net profit of $11.8M.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRKR in relation to earlier this year. Most recently, in August 2016, Richard Packer, a Director at BRKR bought 10,000 shares for a total of $219,661.

Bruker Corp. designs and manufactures scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy and infrared and raman molecular spectroscopy technologies. The company operates its business through two segments: Bruker Scientific Instruments and Bruker Energy and Supercon Technologies. The Bruker Scientific Instruments are organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. Bruker was founded by Günther Laukien and Emil Bruker in 1960 and is headquartered in Billerica, MA.